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CLINICAL TRIAL ISSUES IN INTERMITTENT
CLAUDICATION
86.1
Introduction
B 6.1.1
Scope of Section
Most clinical trials in IC relate to the use of pharma-
cological agents. Surgical treatment is rarely indicat-
ed in patients with IC and has not been the subject of
comparative studies. A number of trials of exercise
programs have been reported and are discussed in
Basic Treatment (B 4.1.2, P 568). Some of the prob-
lems specific to these trials are discussed in that sec-
tion and largely centre around the problem of blind-
ing the patient and the observer as well as the prob-
lem of a suitable comparator treatment. Two compar-
ative studies of angioplasty and exercise programs
are also discussed in that section.
This chapter deals predominantly with the issues
surrounding trials of pharmacological treatment. It
does not attempt to be exhaustive but focuses on
selected controversial aspects of trial methodology.
Until recently, there have been remarkably few good
studies looking at the methodology of such trials; for
instance, it is only very recently that the relative mer-
its of constant versus graded treadmill exercise has
been investigated (see B 6.4.1, Constant Versus
Graded Treadmill Protocol, p 5112). Fundamental
questions such as the reason for the day-to-day vari-
ability in treadmill walking distance, whether such
variability is specific to a particular patient or
whether patients with a very short claudication dis-
tance behave fundamentally differently from those
with a long claudication distance, have not been fully
investigated. There is therefore very little basis for
making firm recommendations based on scientific
evidence. The Recommendations that follow are
based largely on what is perceived to be the current
best advice, rather than firm evidence. The
Recommendations therefore could equally well be
labelled as Critical Issues.
B 6.1.2
Existing Guidelines for Clinical Trials in Intermittent
Claudication
Over the years, a number of guidelines for clinical tri-
als of pharmacotherapy in lC have been proposed by
individual countries in Europe or by the new
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European regulatory authority (Committee for
Proprietary Medicinal Products; CPMP). International
guidelines are sometimes an unhappy compromise
between several different national views and rarely
are supported by solid scientific evidence. National
guidelines are often contradictory. In North America,
no such guidelines have been promulgated. Further
basic research into the methodologies involved are
needed and ideally should be the basis of an interna-
tional, or transatlantic, set of guidelines. The following
Recommendations or advice are proposals based on
extensive discussions among investigators experi-
enced in this field.
B 6.1.3
Reporting Standards for Clinical Trials
Standardisation in reporting of results is crucial, and
the Recommendations of the Committee on Reporting
Standards of the Society for Vascular Surgery and the
North American Chapter of the International Society
for Cardiovascular Surgery! and the Technology
Assessment Committee of the Society of
Cardiovascular Interventional Radiology should be
adopted (see also 0 6, Clinical Trial Issues in Critical
Limb Ischaemia, p S237).2-3
Recommendation 38: Reporting standards for trials
in peripheral arterial disease
The recommendations of the committee on
Reporting Standards of the SVS/ISCVS, and in the
case of new devices the standards of the
Technology Assessment Committee of the SCVIR,
should be adopted where appropriate in all trials
involving patients with peripheral arterial disease.
B 6.1.4
Aims of Trials in Intermittent Claudication
Trials of pharmacotherapy in patients with IC can look
at four issues:
1. Does the new treatment significantly improve clau-
dication distance?
2. Does the new treatment significantly alter the
increased cardiovascular morbidity and mortality
rates of patients with claudication?
3. Does the new treatment Significantly improve qual-
ity of life?
4. Is the new treatment safe and free of important side
effects?
The issue of safety must be incorporated into all tri-
als, but in other aspects there is a fundamental differ-
ence between trials looking at a possible effect on
walking distance and trials looking at cardiovascular
morbidity and mortality rates. In the latter case, the
end point of a fatal on nonfatal cardiovascular event
will occur in only 4% to 6% of patients with IC per
year (see A 2.4, Fate of Patients with PAD, p S14) ,and
for a trial to have sufficient power, a large number of
patients have to be recruited, usually several thou-
sand. For similar reasons, the treatment period has to
be relatively long, usually several years. Trials looking
at pharmacotherapy for improving walking distance
usually require only a few hundred patients, usually
followed up for half a year. Issues relating to inclusion
criteria will also be different. For instance, the initial
ABPI is closely correlated with the risk of a subse-
quent cardiovascular event, but is probably unrelated
to the likelihood of a new pharmacological treatment
increasing walking distance.
There have been relatively few trials of pharma-
cotherapy in patients with IC for the prevention of car-
diovascular events, the largest single trial being the
CAPRIE trial, which involved nearly 6,000 patients
with PAD in a total patient population of nearly 20,000.4
The use of older antiplatelet agents for this indication is
largely based on meta-analyses of a large number of
small trials. The issues relating to trial methodology of
pharmacotherapy for the prevention of cardiovascular
events are not discussed here further. The following
sections relate specifically to trials of pharmacotherapy
aimed at improving walking distance.
B 6.2
Trial Design
There is general agreement that such trials have to be
parallel group, double-blind, and randomised,
B 6.2.1
Comparator Drugs
The discussion of currently available pharmacothera-
py for the treatment of claudication (p S76) suggests
that it is inappropriate to use an active comparator
drug, and therefore placebo-controlled trials are
required.
B 6.2.2
Duration of Treatment and Follow-up
It is not possible to be specific on these issues, but in
view of the fact that the symptom treated is chronic, it
would seem reasonable to prolong treatment for sev-
eral months. Six months is a widely accepted period.
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A relatively short follow-up period, after treatment,
would seem reasonable to ensure that there is no
rebound or carry-over effect and possibly to establish
whether continuing treatment is necessary to maintain
any improvement. Most such claudication trials have
not had a formal follow-up period, but 4 weeks of
observation after treatment would seem reasonable.
Recommendation 39: Design of pharmacotherapy
trials in intermittent claudication
Trials of pharmacotherapy to improve claudication
distance should be double-blind, parallel-group,
randomised, and placebo-controlled. Duration of
treatment should be at least 6 months, and to
exclude a sudden rebound effect, a post-treatment
follow-up period of not less than 4 weeks should be
considered.
B 6.3
Entry Criteria
B 6.3.1
Inclusivity Versus Exclusivity
This IS a recurring controversy in all types of trials in
patients with PAD, and indeed in many other dis-
eases. The issue is whether an inclusive set of entry
criteria is used to include a range of patients with dif-
ferent degrees of disease severity or a set of exclusive
criteria that define a small, tight group of patients with
very similar disease. Arguments in favour of exclusiv-
ity include:
1. Patients entered from a homogenous group.
2. Patients are clearly defined.
3. Differences between treatment and control group in
terms of demographic or other characteristics,
which theoretically may affect the treatment effect,
are eliminated.
4. At least theoretically, the trial conditions are clearly
defined and should be repeatable with similar
results in other centres.
Arguments in favour of inclusivity are:
1. The more inclusive the study, the more it reflects
real life.
2. Recruitment is easier, and fewer study centres are
required.
3. More likely to reveal untoward side effects or drug
interactions.
4. In practice, if the result of the study is positive, the
drug is likely to be used in all patients with that
condition-in this case, claudication. It therefore
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should be demonstrated to be effective in all
patients, unless there is a good reason to exclude a
particular subgroup.
Recommendation 40: Inclusivity versus exclusivity
in selection of patients for clinical trials in periph-
eral arterial disease
On balance, it would seem that the advantages in
favour of inclusivity are greater than those in
favour of exclusivity, and therefore including a
broader range of patients is recommended.
B 6.3.2
Stability and Natural History of the Disease
The natural progression of IC in individual patients is
usually unpredictable (see A 2.4.1, Fate of Local
Disease in the Legs, p 514). Ideally, patients should be
stable before entry into the trial, but in practice most
patients with IC fluctuate quite widely in the severity'
of their symptoms. It is therefore probably only prac-
tical to exclude patients in whom there is a recognised
cause and expectation of rapid change during the
treatment period. Patients with acute onset of claudi-
cation or within the first few months of the onset of
claudication are widely believed to be particularly
likely to fluctuate in their symptoms and should prob-
ably be excluded until the symptom is stabilised to
some extent. The effects of any interventional treat-
ment also often take several months to be fully appar-
ent, and such patients should also be excluded mean-
while.
B 6.3.3
Optimal Background Treatment
This is probably more theoretical than practical, but it
often gives rise to much discussion. The basic treat-
ment of patients with IC is outlined earlier (p 566).
There is no doubt that patients presenting with IC
should have treatment of any coexisting disease, such
as diabetes or hypertension. They also should be
advised about appropriate changes in lifestyle, such as
discontinuing smoking and maximising exercise.
These measures should be taken before entering a
patient into a trial of pharmacotherapy. This may have
practical consequences, as in the treatment of hyper-
tension, where initially there might be a deterioration
in the walking distance because of a decrease in the
central perfusion pressure. However, there is no good
evidence that treatment of diabetes or cessation of
smoking has any marked effect on claudication dis-
tance in the timespan of a few months.
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The issue of exercise is more difficult. As discussed
in section B4.1.2, Basic Treatment, there is good evi-
dence that a supervised exercise program improves
claudication distance, and clearly would be unethical
to withhold this if it were available to the patient.
(supervised exercise programs are not available in
many centres, and many patients are unable or unwill-
ing to participate. A pragmatic solution seems obvi-
ous; that, is taking all of the necessary measures that
would normally be taken locally before entry into a
trial of an individual patient and then continuing with
the same advice and treatment throughout the dura-
tion of the trial.
B 6.3.4
Run-in Phase
The appropriate primary end point for such trials is
some form of walking test (see B 6.4, End Points for
Trials in Intermittent Claudication, p 5112). However,
as discussed previously, the walking distance of indi-
vidual patients varies widely from day to day. There
has therefore been a tendency to perform repeated
walking tests at intervals (of, say, 1 week) and to
exclude patients whose results fall outside preset lim-
its (often 2:20% variation in absolute walking dis-
tance). Much of the argument about inclusivity and
exclusivity applies to this issue as well; applying such
entry criteria may exclude 10% to 30% of otherwise
eligible patients. Furthermore, there is no good evi-
dence that variance at the beginning of the study in
terms of walking distance is related to a variance at the
end of the study period. Nor does the evidence sug-
gest that patients with a wide variance in walking dis-
tance behave fundamentally differently in response to
pharmacotherapy to patients with a smaller variance.
Furthermore, intersubject variability in these studies is
almost always much greater than intrasubject variabil-
ity, and therefore, the latter will have a relatively small
effect on the accuracy of the final result.
A counter argument might be that patients with
wide spontaneous variability in their walking distance
may have a limiting factor other than claudication,
and this may be a reason for the decision to define cri-
teria for baseline treadmill test variability should be
left to the investigators and sponsors responsible for a
particular trial.
Recommendation 41: Entry criteria in clinical trials
for pharmacotherapy and claudicatiOli
Before entry into a drug study, the patient's condi-
tion and walking ability should be relatively stable.
In addition, all other routine measures for the treat-
ment of the condition, such as antiplatelet therapy,
normalising lipids, advising against smoking, exer-
cise, and treatment of coexisting diseases, should
have been instituted. These efforts should be docu-
mented, and patients should achieve a steady state
for these variables before enrollment in a trial.
The extent to which entry variability of walking
distance will affect the outcome of claudication
studies is unknown, and therefore the question of
whether to include stability testing on the treadmill
should be left to the decision of the investigators
and sponsors for the particular trial.
B 6.3.5
Stratification
There are two possible reasons for stratification:
1. To ensure comparability between the active and
control groups in terms of demographic or
. other characteristics that may affect response to
treatment
2 The possibility or probability that the treatment
may be effective only in a subgroup of the
total population
Neither of these reasons is sufficient to justify strat-
ification in the particular context of pharmacotherapy
for Ie, unless there is some good prior information to
suggest that the drug tested may only be efficacious in
a particular type of claudicant. Theoretically, an infi-
nite list of variables, ranging from age and gender to
the presence of diabetes or the anatomic site of the ath-
erosclerosis, could have an effect on the efficacy of the
treatment tested. Stratifying for all these variables
would be practically impossible. It is, of course,
inevitable that even with randomisation there will be
some demographic variable in which the two groups
will be statistically significantly different. This cannot
be avoided and does not matter, unless retrospective
analysis shows that that particular variable was an
independent determinant of efficacy. Furthermore, it
is mathematically quite feasible and, if predetermined
in the protocol, perfectly permissible to adjust the
groups post-hoc if a particular demographic variable
is found to be a significant determinant of efficacy.
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Stratification is often used in clinical studies. If the
patient population is sufficiently large to permit sub-
group analyses, it does not significantly disadvantage
the study. Stratifying because of the possibility that the
new treatment may only be efficacious in a particular
subgroup is illogical. If there is good prior evidence to
suggest that a particular subgroup may behave differ-
ently, then the trial should be powered to be able to
show this, and in reality one is performing two sepa-
rate studies. These arguments apply for most of the
criteria that have on occasions been used to stratify
patients, such as the initial walking distance, presence
of diabetes, or ABPI. There has been no reason to
believe that any of the drugs tested so far in IC would
only be effective in any particular subgroup, although
this may not necessarily be the case for future drugs.
Recominendation 42: Stratification of patients in
intermittent claudication pharmacotherapy trials
In general, there is no need to stratify patients
enrolled in claudication pharmacotherapy trials.
An exception would be in the case of pharma-
cotherapy that may be presumed to be more effica-
cious in one strata of patients as compared with
another, in which case it may be more appropriate
to conduct two separate trials. This may be the case
in diabetic patients, for example.
86.4
End Points for Trials in Intermittent Claudication
The symptom treated is limitation of walking, and
therefore the only appropriate end point is change in
claudication distance. To standardise measurement of
walking distance, a treadmill at a slope has tradition-
ally been used.
B 6.4.1
Constant Versus Graded Treadmill Exercise Protocol
Initially, the treadmill had been used at a fixed speed
and a fixed gradient and the distance or time meas-
ured until the onset of claudication, the lCD, or the
maximum walking distance, that is, the ACD. The
principal problem with the method has been the vari-
ability in the measurement from day to day. This
probably only reflects the variability in claudication
distance reported by patients in their everyday life.
There is general agreement that some of the initial
variability on the treadmill can be eliminated by
familiarising the patient with the method. Most of
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these patients are elderly and have never been asked
previously to walk on a treadmill. Therefore, one or
two trial sessions on a treadmill should precede any
actual measurement of walking distance used in a
trial.
It is also the general impression that some variabil-
ity in the results obtained with this method are attrib-
utable to the influence of the operator, particularly in
relation to the instructions given to the patients test-
ed. The end point is determined by the patient's
interpretation of the sensation in the legs; it is neces-
sarily subjective, and it is possible that this is to some
extent influenced by the effect of the operator. It is
therefore usually recommended that as far as possi-
ble the same operator should be used to test the same
patient on different occasions.s
More recently, it has been suggested that a graded
exercise schedule might be more accurate. In this, the
treadmill is initially horizontal and then the slope is
gradually increased at intervals, keeping the speed
constant. This results in an increasing workload as
the patient continues with the test and has long been
routine practice in performing exercise ECG tests.
The relative merits of a constant versus a graded
treadmill exercise test have been discussed in detail
in Basic Treatment (p S68). After an initial enthusiasm
for the graded test, current evidence suggests that
there is no significant difference in the reproducibili-
ty of the results obtained with the two tests.s?
Similarly, the initial suggestion that the "placebo"
effect previously observed with constant exercise
was not present with graded exercise has not been
borne out by subsequent studies. "Placebo" effect in
this context is probably a misnomer, because
improvement in claudication distance almost invari-
ably observed in the control group could be the result
of a genuine spontaneous improvement in exercise
tolerance of the patient rather than a true placebo
effect.
B 6.4.2
Initial Claudication Distance Versus Absolute
Claudication Distance
A number of studies have looked at the reproducibili-
ty of ICD and ACD, with most showing that the ACD
is more reproducible and therefore presumably the
more appropriate measurement to use as a primary
end point.s? It also has the theoretical justification that
it probably more truly represents real life, where the
patient is likely to continue to walk even after the first
appearance of claudication discomfort, particularly
because most doctors now routinely advise patients to
walk into their claudication discomfort.
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Recommendation 43: Primary end point in inter-
mittent claudication trials-treadmill testing
• The single primary end point that is most appro-
priate in intermittent claudication trials is the
absolute claudication distance on a treadmill.
• Either graded or constant treadmill exercise is
acceptable, but it is essential that they be
performed in a rigorously controIIed and
standardised manner.
• If a patient has not used the treadmill before, then
one or two familiarisation sessions before any
definitive measurements are recommended, and
it is also thought to be advantageous to try to
ensure that the same operator supervises each
test.
. 86.4.3
Statistical Versus Clinical Significance
As with many artificial controversies, this is much
debated. If the difference in the change in the walk-
ing distance in the treated and the control group is
not statistically significant, then the result of the trial
is negative, or unproven, whatever the size of the
mean difference. The only issue is how large the sta-
tistically significant difference between two groups
has to be to make it worthwhile administering the
active treatment. As with all other forms of pharma-
cotherapy in medicine, this is a question of evaluat-
ing the cost/benefit of treatment, incorporating con-
siderations of issues such as side effects, potential
risks, and cost. The argument is often made that a
relatively small, albeit statistically significant,
improvement in active treatment of, say, 20% is
unlikely to result in a significant improvement in the
patient's quality of life. That is precisely why ideally
changes in quality of life should be measured in
these trials (see B 6.4.5, Measurement of Quality of
Life, p 5113).
There is perhaps some logic in deciding to analyse
the data in terms of the number of patients who
managed to achieve an arbitrarily set improvement
in their walking distance-for instance, the number
of patients who can increase their walking distance
by 50% in the control group compared with the
number of patients who can achieve a similar
improvement in the treated group. It is generally
agreed that in analysing the change in walking dis-
tance, a logarithmic scale rather than an arithmetic
scale should be used.
86.4.4
Secondary End Points
Although it is generally agreed that there are no satis-
factory surrogate end points in trials of pharmacother-
apy in Ie, strictly speaking" the treadmill walking dis-
tance is also a surrogate end point. The patient does
not complain of difficulty in walking on the sloping
treadmill but has difficulty in going about their every-
day business. However, the use of a treadmill is
accepted as being close enough to the real situation
and allowing a measurement to be made.
More "distant" end points, such as possible changes
in plethysmographic blood flow or ABPI, may be
measured and could give some useful clues about
mechanisms of action, but they can in no way replace
the measurement of the walking distance as a primary
end point. Although there can be only one primary
end point, there is no reason to limit other relevant
measurements and events, which can all be secondary
end points. This could include changes in lCD, nonin-
vasive measurement of exercising blood flow, or reac-
tive hyperaemia. Approximately 2% of the patients
also develop some major cardiovascular event during
a 6-month trial, and this clearly needs to be recorded.
Apart from possibly giving a clue about mechanisms
of action, such secondary measurements may also add
robustness to the principal result of the primary end
point.
86.4.5
Measurement of Quality of Life
If the quality of life, that is, the actual handicap to the
patient, could be measured accurately, then in princi-
ple it would be the ideal primary end point.
Unfortunately, we are very far from being able to do
so. At least half a dozen different quality-of-life
instruments have been used in patients with IC, but
their validation is exceedingly difficult because there
is no standard to which their accuracy can be com-
pared.5,8,9, l o Many quality-of-life instruments have
been said to have been validated by using that term
quite inaccurately. Such claims have been based on
simply demonstrating reproducibility, which has
nothing to do with true validation, or demonstrating a
close correlation between the results of the quality-of-
life measurement and the treadmill walking distance.
This latter exercise is particularly futile: If a particular
quality-of-life questionnaire could exactly reproduce
the results of a treadmill walking test, then it would
simply become another way of measuring walking
distance and not a true measure of quality of life.
Nevertheless, an accurate measurement of quality of
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life should be the ultimate goal in such trials, and
therefore some of the existing instruments should be
used in all such trials to try and increase our under-
standing of this extremely important but very embry-
onic science.
Recommendation 44: Other end points in intermit-
tent claudication trials
• There are no appropriate surrogate end points for
claudication distance, however measured, in trials
of intermittent claudication.
• Other possibly relevant data should be collected
because they will add robustness to any positive
result and may give a clue regarding the mecha-
nism of therapy action.
• Quality-of-life instruments should be used in all
trials, and ultimately this may become a primary
end point.
• Cost data should be documented over the dura-
tion of the trial.
86.5
Trials of Prevention of Cardiovascular Morbidity
and Mortality in Intermittent Claudication
The most serious risk for a claudicant is not the threat
of requiring an amputation, which is approximately
2%, but rather the high incidence of nonfatal and fatal
cardiovascular events, which occur in approximately
4% to 5% of claudicants per year. Prevention trials
looking at modifying this systemic risk are relatively
recent, and the methodology is still not fully devel-
oped. Entry criteria are usually very inclusive, encom-
passing all patients with symptomatic PAD and often
also including patients who had PAD in the past but
may now be asymptomatic as a result of some form of
intervention. To obtain sufficient event rates and clin-
ical relevance, such prevention trials are usually much
longer than studies simply looking at walking dis-
tance. Two years or more is suggested. The same argu-
ments apply for and against stratification, as in trials
of walking distance.
An adequate end point in prevention studies is a
composite end point comprising nonfatal ischemic
stroke, myocardial infarction, cardiovascular death,
and possibly coronary and carotid revascularisation
and major amputation, whichever occurs first. As
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such, trials are inevitably multicentre and usually
multinational. It is essential to standardise and verify
the end-points. World Health Organisation criteria for
the diagnosis of coronary events and strokes are usu-
ally adopted. In the optimal case, total mortality may
be the most relevant end points; however this proba-
bly requires an exceptionally large number of patients.
Combining nonfatal cardiovascular morbidity with
all-cause mortality involves comparison of unequal
entities. A combination end point using cardiovascu-
lar mortality has been criticised because survival, irre-
spective of the cause of death, is what ultimately mat-
ters. Such a concern may be mitigated if it can be
shown that the results for the primary composite end
point are statistically significant, that in the optimal
case cardiovascular mortality is significantly reduced,
and that the change in cardiovascular mortality also
favourably influences all-cause mortality. There is
probably little place in such trials for quality of life
end points.
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